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Abstract
Background: Lipids have become an important target for searching new biomarkers typical of different
autoimmune and allergic diseases. The most common allergic dermatitis of the horse is related to stings of insects
and is known as insect bite hypersensitivity (IBH) or summer eczema, referring to its recurrence during the summer
months. This intense pruritus has certain similarities with atopic dermatitis of humans. The treatment of IBH is
difficult and therefore new strategies for therapy are needed. Autoserum therapy based on the use of serum
phospholipids has recently been introduced for horses. So far, serum lipids relating to these allergic disorders have
been poorly determined. The main aim of this study was to analyse phospholipid profiles in the sera of horses with
allergic dermatitis and in their healthy controls and to further assess whether these lipid profiles change according
to the clinical status after therapy.
Methods: Sera were collected from 10 horses with allergic dermatitis and from 10 matched healthy controls both
before and 4 weeks after the therapy of the affected horses. Eczema horses were treated with an autogenous
preparation made from a horse’s own serum and used for oral medication. Samples were analysed for their
phospholipid content by liquid chromatography coupled to a triple-quadrupole mass spectrometer (LC-MS). Data
of phospholipid concentrations between the groups and over the time were analysed by using the Friedman test.
Correlations between the change of concentrations and the clinical status were assessed by Spearman’s rank
correlation test.
Results: The major phospholipid classes detected were phosphatidylcholine (PC), sphingomyelin (SM),
phosphatidylinositol (PI) and phosphatidylethanolamine (PE). Eczema horses had significantly lower total
concentrations of PC (p < 0.0001) and SM (p = 0.0115) than their healthy controls. After a 4-week therapy, no
significant differences were found between the groups. Changes in SM concentrations correlated significantly
with alterations in clinical signs (p = 0.0047).
Conclusions: Horses with allergic dermatitis have an altered phospholipid profile in their sera as compared
with healthy horses and these profiles seem to change according to their clinical status. Sphingomyelin seems
to have an active role in the course of equine insect bite hypersensitivity.
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Background
Various new and important insights into the roles of lipids
have been demonstrated over the past few decades. Most
of these findings are related to inflammatory and immune
responses including studies on pro-resolving lipid media-
tors [1, 2], lipid antigens [3, 4] and lipid presenting CD1
molecules [5–7]. Mass spectrometry with specific software
applications has made it possible to identify and quantify a
multitude of lipid species both in mammalian cells and
also of those existing in circulation [8–12]. Although
phospholipids are commonly present in mammalian sera
[13, 14], changes in their concentrations under various
pathological conditions are so far poorly understood
[9, 15, 16]. Presently, there is an increasing need to
find new biomarkers feasible for diagnosis, treatment and
prognosis – not only in allergic diseases, but also in other
immune mediated and neurological disorders [2, 16–23].
Insect bite hypersensitivity (Fig. 1a) is the most com-
mon allergic skin disease of the horse [24] displaying
many features similar to atopic dermatitis (AD) of
humans [25, 26]. Intense and recurrent pruritus, IgE-
mediated responses, perivascular mast cell, eosinophil
and T-lymphocyte infiltrations are typical findings of
both disorders [25, 27–32]. In addition, horses with in-
sect hypersensitivity show IgE-mediated sensitization
also to various environmental allergens [27], as do patients
with atopic dermatitis [31, 32]. However, disturbed skin
barrier function due to inherited defects of filaggrin has
not been studied on horses [26]. Treatment of equine IBH
is challenging, since total isolation from biting insects is
impossible. Antihistamines or allergen-specific immuno-
therapy have not been beneficial [33, 34]. Therefore there
is a need for comprehensive understanding of this harmful
disease. In our previous study [35], we analysed phospho-
lipid contents of autoserum preparations that have been
recently used in the therapy of insect hypersensitivity in
horses. The idea is to collect remnant lipid particles in
these preparations after serial washings [35]. Concentra-
tions of phosphatidylcholine (PC) and sphingomyelin
(SM) were significantly more abundant in the preparations
made from the sera of the affected than from healthy
horses and the amounts of these phospholipids showed
significant associations with the severity of prevailing clin-
ical status [35].
The purpose of the current study was to analyse by li-
quid chromatography-mass spectrometry (LC-MS) phos-
pholipids in the sera of horses with insect bite allergic
dermatitis and in their matched healthy controls. We
hypothesize that phospholipid profiles may differ be-
tween the groups. The additional aim was to assess
whether these profiles change according to the clinical
status after autoserum therapy.
Results
The main phospholipid classes analysed were phosphat-
idylcholine (PC), phosphatidylethanolamine (PE), phos-
phatidylserine (PS), phosphatidylinositol (PI), phosphatidic
acid (PA) and sphingomyelin (SM). Of these, all except for
PS were detected across all the samples. Relative contents
of the major phospholipid classes before (stage 0) and
after the 4-week therapy (stage 4) of eczema horses are
listed in Table 1. In addition to the major phospholipid
classes, all the samples also contained PA 36:2 and lysoPC
species of 16:0, 18:2 and 18:0.
Phosphatidylcholine was the most abundant of all the
phospholipid classes detected (Table 1). Its major mo-
lecular species in both eczema and control horses at
stages 0 and 4 are presented in Figs. 2 and 3, respect-
ively. Of the molecular species, PC 36:2 was the most
abundant. Additionally, trace amounts of PC 26:0, 28:0,
31:1, 33:1, 33:2, 33:3, 36:2, 36:3, 36:6 and 38:8 were de-
tected. In the samples collected later in the summer
(Table 2), PC concentrations were found to be more abun-
dant than in the samples taken earlier (Figs. 2 and 3).
Horses in the eczema group had a significantly lower total
concentration of PC than healthy horses before the start
of the therapy (Table 3). After the 4-week therapy, no sig-
nificant difference could be found between the groups
(Table 3, Fig. 3). In the eczema group, the total PC con-
centration had increased significantly, while in the control
Fig. 1 Typical clinical signs in the tail of a horse with insect bite allergic dermatitis (a) and the same horse after a 4-week therapy (b)
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group there was a small decrease (Figs. 2 and 3). Concen-
trations of all the major molecular species presented in
Figs. 2 and 3 increased significantly (at level p < 0.05) in
the affected horses between stages 0 and 4, while in the
healthy horses, the only significant change observed was a
decrease in the concentration of PC 40:8 (P = 0.0007).
Concentrations of SM were found to be significantly
lower in eczema horses in comparison with their healthy
controls at stage 0 (Table 3), although the relative con-
tent of SM was higher in the affected horses (Table 1).
The total SM concentrations decreased in both groups
during the study period (Table 3, Figs. 4 and 5) and at
the second sampling there was no significant difference
observed between the two groups (Table 3). The major
SM species detected and their changes between the
stages 0 and 4 are shown in Figs. 4 and 5. The most
abundant species was SM 20:0 in both groups and its
concentration differed neither between the groups nor
the stages. Concentrations of SM 16:0, 18:0, 24:0 and
24:1 decreased significantly (at level p <0.05) between
the stages in both eczema and healthy horses. Concentra-
tions of SM, like PC, were more abundant in the samples
collected later in the summer (Table 2, Figs. 4 and 5).
Phosphatidylinositol and PE displayed small amounts
of the phospholipids detected (Table 1). Of PI, molecular
species of 32:0, 34:1, 34:2, 36:1, 36:2, 36:3, 36:4 and 38:4
were found. The pairwise comparisons showed no sig-
nificant differences between the two groups at any stages
(Table 3). The detected molecular species of PE were
that of 32:0, 36:1, 36:2, 36:3, 36:4, 38:4 and 38:5. Unlike
PI, the amounts of PE increased significantly from stage
0 to 4 in both groups (Table 3). However, its relative
content did not change due to its small total amount
(Table 1). No significant differences between the groups
were observed at any of the stages.
Five of the horses had mild and 5 moderate clinical
signs at the beginning of the study and the total score of
signs was 15, according to the 3-graded scale used. After
a 4-week autoserum therapy, the signs had relieved in 6
horses (Fig. 1b), remained unchanged in 3, while one
horse suffered from aggravated clinical signs, the total
score being 10. Horses with positive clinical outcome
showed a milder decrease in SM concentrations than
horses with poorer response or controls (Fig. 6). The
change in total SM concentrations correlated signifi-
cantly with alterations in the clinical signs (P = 0.0047)
and of the major molecular species, SM 15:0 exhibited a
significant correlation (P = 0.0268). None of the other
phospholipid classes showed significant correlations with
the change of clinical signs.
No side effects relating to the therapy were observed.
Control horses did not develop signs typical of IBH dur-
ing the study period.
Discussion
The purpose of this study was to analyse the major phos-
pholipids typical of mammals in the sera of healthy horses
and horses with allergic dermatitis. The additional aim
was to assess whether profiles of the detected phospho-
lipids change according to clinical status when horses
were treated with an autogenous serum preparation. In
Table 1 Relative contents of the major phospholipids detected
in sera of the horses
Phospholipids Relative content (mean ± sd/%)
Eczema group Control group
Stage 0
PC 76.0 ± 4.8 83.3 ± 9.8
SM 21.9 ± 3.8 14.8 ± 8.5
PI 1.9 ± 1.4 1.7 ± 1.5
PE 0.2 ± 0.2 0.2 ± 0.2
Stage 4
PC 87.4 ± 1.7 85.6 ± 2.7
SM 11.0 ± 1.6 12.4 ± 1.9
PI 1.4 ± 0.7 1.8 ± 1.3
PE 0.2 ± 0.2 0.2 ± 0.2
Samples of horses with allergic dermatitis (n = 10) and their matched healthy
controls (n = 10) are collected before treatment (stage 0) and when affected
horses have been on autoserum therapy for 4 weeks (stage 4). Phospholipid
classes: phosphatidylcholine (PC), sphingomyelin (SM), phosphatidylinositol
(PI), phosphatidylethanolamine (PE).
Fig. 2 Concentrations of the most abundant phosphatidylcholine (PC) species at the start of therapy. Eczema horses (n = 10) and their matched
healthy controls (n = 10) are numbered similarly. All species showed significantly lower concentrations in eczema horses, at level P < 0.0001
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our previous study [35], we found that autoserum prepa-
rations made from the sera of healthy horses and from
horses with allergic eczema showed significantly different
phospholipid profiles. Additionally, lipid concentrations
displayed significant relationship with the severity of clin-
ical signs. Therefore, the present study was focused on
serum and changes observed in its lipid profiles in re-
sponse to autoserum therapy, but not on the clinical effi-
cacy of this therapy per se.
Horses with insect hypersensitivity showed signifi-
cantly lower total concentrations of PC and SM than
their matched healthy controls. After a 4-week therapy,
those differences faded. The cause of these originally
lower concentrations in eczema horses is unclear. Obser-
vations from earlier studies indicated that small children
with elimination diets or horses fed with oil supplements
show altered lipid compositions in their sera [36, 37]. In
addition, fasting influences lipid concentrations [9]
which stresses the relevance of matching and equal tim-
ing when blood is collected from non-fasting horses and
their controls. Horses suffering from severe clinical signs
may spend time for scratching and thus eat differently
than healthy horses. However, none of the horses were
so severely affected. Eczema horses were otherwise in a
normal physical condition without signs of emaciation
and their feeding regimen and daily activities were similar
to their controls, neither had the owners observed any
changes in their appetite. Although the feeding regimen
was similar between the horses, there could be a possibil-
ity that some unknown factors might have influenced the
lipid concentrations over time, since sera collected in the
late summer showed more abundant concentrations of PC
and SM than did sera collected earlier in the summer and
this trend was detectable in both affected and healthy
horses. This emphasizes the importance of matching ac-
companied by simultaneous samplings in these kinds of
studies that are prone to environmental impacts.
Phosphatidylcholine, the major phospholipid present in
mammalian sera [13, 14], was found to be the most abun-
dant also in the present study. In humans, alterations in
its concentrations have been linked to various pathological
conditions, such as cancer, atopic dermatitis and type-1
diabetes, where in altered levels of both PC and SM in
sera have been observed [17, 22, 23, 38]. Fuchs et al.
showed that in rheumatoid arthritis, PC/lysoPC ratio
acted as an indicator of this autoimmune disease and add-
itionally, an increased ratio seemed to be associated with
the success of the therapy [39]. LysoPC is a derivative of
Fig. 3 Concentrations of the most abundant phosphatidylcholine (PC) species after a 4-week therapy. Eczema horses (n = 10) and their matched
healthy controls (n = 10) are numbered similarly. Concentrations of PC 34:1 and 36:1 were significantly lower in eczema horses, while 40:8 was in
the controls, at level P < 0.05
Table 2 Matching of the horses
A Breed Gender Age (years) Feed B Breed Gender Age (years) Feed Date of 1stsample
1 Finnhorse ♀ 3 same fodder 1 Finnhorse ♀ 9 same fodder 24 April
2 Icelandic horse ♀ 22 same fodder 2 Shetland pony ♀ 22 same fodder 21 May
3 Icelandic horse ♀ 23 same fodder 3 Icelandic horse ♂ 9 same fodder 21 May
4 Finnhorse ♂ 8 same fodder 4 Finnhorse ♂ 7 same fodder 12 June
5 Finnhorse ♂ 8 same fodder 5 Finnhorse ♂ 7 same fodder 12 June
6 Finnhorse ♀ 8 same pasture 6 Finnhorse ♀ 8 same pasture 12 June
7 Finnhorse ♀ 4 same pasture 7 Finnhorse ♀ 7 same pasture 17 July
8 Finnhorse ♀ 4 same pasture 8 Finnhorse ♀ 6 same pasture 11 Aug.
9 Icelandic horse ♀ 10 same fodder 9 Icelandic horse ♀ 29 same fodder 7 Sept.
10 Finnhorse ♀ 11 same pasture 10 Finnhorse ♀ 19 same pasture 12 Sept.
A) 10 horses with allergic dermatitis and B) their 10 matched healthy controls. The horse and its matched control are numbered similarly
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PC and it is easily formed from PC during storage at room
temperature [40]. In horse sera, the relative content of
lysoPC is small [14] and therefore it is not an applicable
marker in horses as it is in humans. In the present study,
lysoPC was detected in minor concentrations and conse-
quently was not evaluated further. Although there was a
highly significant difference in PC concentrations between
the healthy and the eczema horses at the first sampling,
PC did not show any correlation with the change in
clinical signs, neither was there any prognostic association
between the first PC concentrations and the response to
therapy. In contrast to our horse study, higher levels of
PC predicted better outcome in patients with atopic ec-
zema after monoclonal antibody therapy [38].
Concentrations of SM were significantly lower in the
affected than in healthy horses before the treatment, but
not afterwards. Therefore, the elevated relative content
of SM in eczema horses at the first sampling is in par-
ticular due to the lower levels of PC. Surprisingly, the
amounts of SM decreased significantly among the con-
trol horses during the study period, which demonstrates
that concentrations of certain lipids may fluctuate in
healthy horses, at least to some extent without largely
undermining the relative lipid content. This fluctuation
possibly resulted from environmental changes, since SM
concentrations decreased also in eczema horses. However,
the decrease was evident only in those eczema horses that
showed a poorer outcome in response to therapy. This
suggests that affected horses have a specific need for SM
during recovery. Sphingomyelins are important lipids in-
volved in multiple biochemical reactions, especially in the
skin and nervous tissue [15, 41–43]. These phospho-
lipids are necessary not only as structural components,
but also as bioactive regulators and messengers in cuta-
neous homeostasis and immune mediated responses,
particularly via the main derivative, sphingosine-1-
phosphate [41, 42, 44, 45]. Sphingosine-1-phosphate
(S1P) plays a crucial part in mast cell regulation by af-
fecting mast cell degranulation and by activating other
immune cells involved [44, 45]. The engagement of S1P
to its receptors on the plasma membrane seems to be
the most critical point in the pathway of mast cell acti-
vation [44–46]. In addition to S1P, ceramide is another
important metabolite of SM and is one of the main lipid
components in skin barrier [41]. In the affected skin,
ceramides are continuously utilised for repairing [41].
Although various lipid combinations and their changes
Table 3 Pairwise comparisons of serum phospholipid
concentrations
PC 0 PC 4 PC 0 c PC 4 c
PC 0 p = 0.0007 p < 0.0001 p < 0.0001
PC 4 p = 0.0007 ns ns
PC 0 c p < 0.0001 ns ns
PC 4 c p < 0.0001 ns ns
SM 0 SM 4 SM 0 c SM 4 c
SM 0 ns p = 0.0115 ns
SM 4 ns p = 0.0005 ns
SM 0 c p = 0.0115 p = 0.0005 p = 0.0186
SM 4 c ns ns p = 0.0186
PI 0 PI 4 PI 0 c PI 4 c
PI 0 ns ns ns
PI 4 ns ns ns
PI 0 c ns ns ns
PI 4 c ns ns ns
PE 0 PE 4 PE 0 c PE 4 c
PE 0 p = 0.0058 ns p < 0.0001
PE 4 p = 0.0058 ns ns
PE 0 c ns ns p = 0.0018
PE 4 c p < 0.0001 ns p = 0.0018
Phosphatidylcholine (PC), sphingomyelin (SM), phosphatidylinositol (PI) and
phosphatidylethanolamine (PE) detected from horses with allergic dermatitis
and from their matched healthy controls (c); samples collected before (0) and
4 weeks after (4) the therapy of the affected horses
Fig. 4 Concentrations of the most abundant sphingomyelin (SM) species at the start of therapy. Eczema horses (n = 10) and their matched
healthy controls (n = 10) are numbered similarly. Species of SM 15:0 and 24:1 showed significantly lower concentrations in eczema horses, at
level P < 0.05
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in response to therapy have been linked to atopic
dermatitis in humans [38, 47], SM seems to be a poten-
tial player in insect bite allergy of the horse, since alter-
ations in its concentrations were significantly associated
with changes in clinical signs. Similarly, sphingolipids
have been shown to act as biomarkers in delayed type
hypersensitivity of mice [16].
In our study, both PI and PE were detected in minor
amounts, which is consistent with the previous studies
[14]. These phospholipids are probably not involved in
insect bite hypersensitivity, since there was no difference
between the groups in the first sampling and the con-
centrations of PE changed similarly in both groups.
Traces of PA were found in all samples and as an inner
leaflet phospholipid, it is not normally detected from the
horse serum [14]. Presence of PA is probably related to
blood cells that remained when the samples were har-
vested without centrifugation [35].
Horses in the present study were treated with an auto-
serum preparation and phospholipids were analysed in
response to this treatment. However, we had no control
group for the therapy; therefore it is not relevant to con-
clude that the observed changes could be specific for the
current treatment. In fact, further studies are needed to
evaluate a relationship between phospholipid concentra-
tions and responses to therapy, comprising placebo or
other therapeutic interventions and a greater number of
horses than those enrolled in this study.
The lower concentration of PC and SM detected in
the sera of affected horses was an unexpected finding,
since our earlier study demonstrated that autoserum
preparations made from the sera of horses with allergic
dermatitis showed significantly higher concentrations of
PC and SM than the preparations made from the sera of
healthy horses [35]. This contradictory result may be as-
sociated with the hydrophobic/hydrophilic interactions
of the lipid particles. The serum for autoserum prepara-
tions was collected from the superficial layer of the
blood sample, washed twice with water and finally added
in ethanol; all consecutive transfers were collected from
the superficial layer of the previous solution [35]. Thus
the most hydrophobic and water-insoluble lipid mole-
cules were presumably concentrated in such autoserum
preparations. Instead of washings, samples of the present
work were mixed directly with alcohol. Therefore, these
samples included not only the most hydrophobic but
also the less hydrophobic lipid particles, such as PC 26:0
with a short acyl chain or PC 36:6, 38:8 and 40:8 with
several double bonds; species that were not detected in
autoserum preparations [35]. The discrepancy with the
amounts of PC and SM in the serum versus autoserum
preparations may be interpreted as so far unknown,
hydrophilic/hydrophobic interactions possibly linked to
mineral salts that have been found to affect peculiarly
the distribution of lipids after successive washings [48].
Sera of affected horses may contain those mineral salts
Fig. 5 Concentrations of the most abundant sphingomyelin (SM) species after a 4-week therapy. Eczema horses (n = 10) and their matched
healthy controls (n = 10) are numbered similarly. Concentrations of SM 18:0 and 21:0 were significantly lower in eczema horses, at level P < 0.05
Fig. 6 Difference of sphingomyelin (SM) concentrations (pmol in total of
0.5 ml) after therapy. The change between the pre (stage 0-week) and
the post (stage 4-week) concentrations in eczema horses with (A, n= 6)
and without (B, n= 4) a positive clinical response and in their matched
healthy controls (Ac and Bc, respectively)
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that make lipids less water-soluble and enable them to
concentrate into autoserum preparations, although ac-
cording to the current study the total concentrations of
PC and SM were lower in these horses. This interpret-
ation could explain with caution the underlying mechan-
ism of this therapy, possibly culminating in the ability of
signalling molecules to engage their corresponding re-
ceptors which has been recognized to be a critical event
for the following mast cell responses [44–46].
Conclusions
Horses with an allergic dermatitis have an altered lipid
profile in their sera as compared with healthy controls and
these differences seem to change according to the clinical
status of the horses. Sphingomyelin shows a functional
role in equine insect bite hypersensitivity. Lipid profiling
may become an important target for further studies,
since relevant fingerprints delineating different patho-
logical disorders are needed – in both human and veter-
inary medicine.
Methods
Horses
A total of 20 horses entered in this study in 2014, be-
tween the seasons of spring and autumn, the period
when horses are exposed to bites of insects. The horses
comprised 10 animals with clinical signs of insect bite
hypersensitivity (eczema group) and 10 matched healthy
controls (control group). The matching is presented in
Table 2. Clinical signs of eczema were categorised as
mild, moderate or severe at the time of blood sampling
and scored 1–3, respectively. Signs were mild, if the
horse had only pruritus without skin lesions. Pruritus
with mild skin affections in the mane, tail (Fig. 1a) and/
or body was graded as moderate, while pruritus over
large skin lesions was regarded as a severe sign. Clinical
signs were evaluated after the 4-week therapy and con-
sidered as relieved when signs became milder on this
scale (Fig. 1a and b). The changes in clinical signs were
recorded as relieved, no change or aggravated and re-
spectively scored as −1, 0 or +1. Five of the horses had
mild and 5 moderate clinical signs in the beginning of
the study. The matched healthy controls without a his-
tory of IBH lived in the same farms and were fed with
the similar fodder as their affected counterparts. Horses
were also matched with breed, gender and age as closely
as possible (Table 2). The eczema horse and its matched
control are numbered similarly in the tables and figures
throughout this article. This study has been approved by
the Regional State Administrative Agency of Southern
Finland (ESAVI/1016/04.10.07/2014) and owners’ signed
permission for inclusion was obtained.
Blood sampling
The first sample (marked as stage 0 in text, tables and
figures) was taken when the horse had shown typical
clinical signs of IBH for at least 2 weeks. Blood sample
was first collected using 10 ml plain vacuum tubes that
were filled in full and kept at room temperature for at
least 3 hours before harvesting. The serum was har-
vested without using a centrifuge, thus avoiding destruc-
tion of serum lipids. With a calibrated pipette, 0.065 ml
of the serum was taken from the superficial layer and
stored in 4.2 ml of 48 % ethanol. The second sample
(marked as stage 4 in text, tables and figures) was col-
lected after a 4-week therapy of the affected horse and
handled equally. Samples were drawn from the counter-
part horse similarly and simultaneously.
Therapy of the eczema horses
All horses in the eczema group were treated with an oral
administration of an autoserum preparation for 4 weeks.
Sera used for the preparations were drawn at the time of
the first blood sampling. Sera were harvested without
using a centrifuge and 0.065 ml of the serum was taken
from the superficial, lipid-containing layer of the tube.
Lipid particles were washed twice with sterile water
(1:100), accordingly 0.065 ml collected from the superfi-
cial layer of the previous dilution. After the second
washing, 0.065 ml was taken from the superficial layer of
the latter solution and added finally in 48 % ethanol
(1:100) and absorbed in sugar granules [49]. A dose of
granules was given orally once a day for 2 weeks,
followed by a 1-week pause, after which horses were
medicated for one further week. Horses in the control
group received no therapy.
Lipid analysis of the sera
Phospholipid classes analysed were PC, PE, PS, PI, PA
and SM. All the samples stored in ethanol were sub-
jected to Folch’s method [48] for lipid extraction, dried
under a N2 stream, reconstituted in 500 μl chloroform/
methanol (1:2) and further spiked with the following la-
belled standardsa corresponding to each head group:
D9(di-44:2) and D9(di-40:2) for PC, D4(di-40:2) and
D4(di-20:0) for PE, D3(di-40:2) and D3(di-44:2) for PS,
D6(di-36:2) and D6(di-28:0) for PI and finally unlabelled
25:0-SM. Liquid chromatography-mass spectrometry
(LC-MS) with selective reaction monitoring (SRM) was
used for the analyses. Waters ACQUITY Ultra Perform-
ance LC systemb equipped with a Waters ACQUITY BEH
C18 column (1.0 × 100 mm) was used to separate the mo-
lecular species using gradient elution. Solvent A was aceto-
nitrile/H2O (60:40) with 10 mM ammonium formate and
1 % NH4OH, while solvent B was isopropanol/acetonitrile
(90:10) containing 10 mM ammonium formate and 1 %
NH4OH. The flow rate was 0.13 ml/min and the column
Hallamaa and Batchu Lipids in Health and Disease  (2016) 15:45 Page 7 of 9
temperature 60 °C. Solvent B was set to 40 % at in-
jection and increased linearly to 100 % in 14 min,
remained at this value for 3 min, decreased back to
40 % in 1 min and then remained there until the end
of the gradient at 20 min. The eluent was directed to
the electrospray ionization (ESI) source of Waters
Quattro Premier triple-quadrupole mass spectrome-
terb operated in the positive ion mode. For SRM tran-
sitions, proton adducts of the PC, PE, PS and PI
species were selected as the precursors, while the
product ion was either the head group (PC, SM, PI)
or the diacylglycerol fragment (PE, PS). For quantifi-
cation purposes, the SRM chromatograms were
integrated and the relative concentrations of the indi-
vidual molecular species were calculated using Quan-
Lynx softwareb.
Researchers processing the samples for mass spectro-
metric analyses were not aware of the horses’ grouping.
The researcher who performed clinical examinations re-
corded these results to another, independent researcher
before the lipid analyses were made. When all studies
were completed, the clinical results were combined to
corresponding lipid profiles under the control of the in-
dependent supervisor.
Data analysis
The Shapiro-Wilk test was used to assess the normality
of lipid concentration data. Uniformly parametric distri-
bution was found neither in the separate phospholipids
classes nor at the different stages. Therefore, pairwise
comparisons of phospholipid concentrations between
the matched groups and over the time were analysed by
using the Friedman test. The relationship between the
change of phospholipid concentrations and clinical signs
was evaluated by Spearman’s correlation test. Analyses
were performed using statistical software StatsDirectc.
Two-sided P values <0.05 were considered significant.
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